Skip to content

Study · Animal study (in vivo) · mongolian gerbil · 1994

3 results

Protective effects of serum thymic factor to Leptospira interrogans serovar Copenhageni infection in Mongolian gerbils.

Yukawa M, Mochizuki K, Kosaka T, Kamata H, Awaya A, Kobayashi H, Onodera T

Veterinary microbiology1 Jul 1994Cited by 2 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Mongolian gerbils given small leptospiral challenge doses, FTS treatment significantly reduced mortality versus controls.

    In plain wordsIn Mongolian gerbils given small leptospiral challenges, FTS reduced deaths compared with controls.

    Outcome
    DecreaseMortality after small challenge doses
    Study

    Mongolian gerbiln: not reported in source

    Mongolian gerbils with or without leptospiral infection
    Comparator
    controls
    Outcome group
    Mortality · Whole body
    Studied dose
    10 microgramsAs given in this study (Mongolian gerbil).

    Source sentences

    Summary
    Mortality of FTS-treated gerbils was significantly lower than that of controls when small challenge doses were used.
    2 context sentences
    Summary · context
    The susceptibility to Leptospira interrogans serovar copenhageni in Mongolian gerbils treated with 10 micrograms of serum thymic factor (FTS) 1 day before infection was examined.
    Summary · context
    Susceptibility of gerbils treated 5 times with 10 micrograms of FTS was also investigated.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In Mongolian gerbils with or without leptospiral infection, FTS did not alter macrophage activity.

    In plain wordsIn Mongolian gerbils with or without leptospiral infection, FTS did not change macrophage activity.

    Outcome
    No significant changeMacrophage activity
    Study

    Mongolian gerbiln: not reported in source

    Mongolian gerbils with or without leptospiral infection
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10 microgramsAs given in this study (Mongolian gerbil).

    Source sentences

    Summary
    Macrophage activity was unaltered but NK cell activity was enhanced in FTS-treated gerbils, with or without leptospiral infection.
    2 context sentences
    Summary · context
    The susceptibility to Leptospira interrogans serovar copenhageni in Mongolian gerbils treated with 10 micrograms of serum thymic factor (FTS) 1 day before infection was examined.
    Summary · context
    Susceptibility of gerbils treated 5 times with 10 micrograms of FTS was also investigated.
  3. 03AnimalAnimal study (in vivo)Activity measurement

    In Mongolian gerbils with or without leptospiral infection, FTS enhanced natural killer cell activity.

    In plain wordsIn Mongolian gerbils with or without leptospiral infection, FTS increased natural killer cell activity.

    Outcome
    IncreaseNatural killer cell activity
    Study

    Mongolian gerbiln: not reported in source

    Mongolian gerbils with or without leptospiral infection
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    10 microgramsAs given in this study (Mongolian gerbil).

    Source sentences

    Summary
    Macrophage activity was unaltered but NK cell activity was enhanced in FTS-treated gerbils, with or without leptospiral infection.
    2 context sentences
    Summary · context
    The susceptibility to Leptospira interrogans serovar copenhageni in Mongolian gerbils treated with 10 micrograms of serum thymic factor (FTS) 1 day before infection was examined.
    Summary · context
    Susceptibility of gerbils treated 5 times with 10 micrograms of FTS was also investigated.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.